Mizuho raises price target on Insmed to $110 after positive Phase 2b results.

From Yahoo Finance: 2025-06-18 10:53:00

Insmed Inc. (NASDAQ:INSM) named one of the 10 best growth stocks by billionaires. Mizuho analyst raises price target to $110 after positive Phase 2b results for TPIP in treating pulmonary arterial hypertension. Analyst confident in TPIP’s potential impact on Insmed’s long-term value. Company also developing ARIKAYCE and other therapies.

Analyst believes successful trial strengthens Insmed’s growth outlook. Company has commercial product ARIKAYCE and pipeline with clinical-stage programs brensocatib, TPIP, and INS1201. While INSM shows investment potential, certain AI stocks may offer greater upside potential. See report on best short-term AI stock for more information.



Read more at Yahoo Finance: Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110